Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This study evaluated the real-world safety of Tepotinib for treating NSCLC with METex14 skipping mutations, confirming known adverse events and identifying new signals like deafness and taste disorder, especially highlighting early monitoring.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

In this case study, administration of prednisolone and Bactrim for a woman with Cronkhite-Canada syndrome led to the cessation of diarrhea, increased serum protein, and improvement in hyperpigmentation and hair regrowth.

This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.

This study found that both intralesional PRP and corticosteroids are effective for alopecia areata, but PRP offers higher patient satisfaction and fewer side effects, despite a slower initial response.

This case study reports that a pediatric patient with recalcitrant alopecia areata was treated using a 308 nm excimer lamp and topical tofacitinib 2% gel.

In this study, treatment of alopecia areata, totalis, and universalis with methyl prednisolone and ACTH injections resulted in complete regrowth in 62% of male and 58% of female patients.

This article reviews common skin eruptions in chemotherapy patients and discusses how recognizing these patterns can help avoid unnecessary changes to cancer treatment; it reports no new clinical results.

In this study, the authors found that targeting mTORC1 with rapamycin inhibited TPA-induced skin tumor promotion by affecting keratinocyte proliferation, including critical stem cell populations in the mouse epidermis.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

This study describes a case of erlotinib-induced alopecia, unresponsive to traditional corticosteroid treatments, that was successfully managed with doxycycline, suggesting a novel approach for EGFR inhibitor-associated alopecia.

This study reviewed evidence suggesting that systemic corticosteroids, particularly in pulse regimens like dexamethasone and betamethasone oral mini-pulse, effectively slow vitiligo progression and support repigmentation, while offering a favorable safety profile compared to continuous therapy.

This study suggests that cedrol may improve mitochondrial function, gut microbiota, and intestinal barrier integrity, indicating its potential value in treating inflammatory bowel disease.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

This study reviewed 20 studies and found that pulse corticosteroid therapy led to complete hair regrowth in 38.53% of patients with severe alopecia areata, but came with many unwanted side effects.

This study identified a cytochrome P450 enzyme, CYP-pa1 from Pseudonocardia autotrophica, as responsible for the specific hydroxylation of cyclosporin A at the 9th N-methyl leucine, suggesting potential for biotechnological applications.

Topical corticosteroids are effective for skin conditions but can have side effects.

This study found that locally injected zalutumumab in healthy volunteers induced a papulopustular rash similar to systemic EGFR inhibitors, and that IL-8 inhibition reduced this dermatological side effect.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

This study found that oral cyclosporine was more effective than betamethasone minipulse therapy for treating Alopecia Areata, with more patients in the cyclosporine group showing excellent and good responses compared to the betamethasone group.

This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.

In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.

Stopping methotrexate might reverse lymphoma-like conditions in some patients.

This study demonstrated that de novo designed bifunctional proteins can target and degrade BCL-xL, leading to cell apoptosis, suggesting a new approach to targeted protein degradation therapy.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

This study found that combined therapy with cetirizine and topical steroids stabilized inflammation in most patients with lichen planus pilaris, though one patient experienced cardiac arrhythmia.

This study developed a topical botanical lotion for managing chemotherapy-induced hair loss in cancer patients, reporting that it improved hair recovery times by 5-16 weeks, reduced inflammation, and enhanced scalp collagen levels with no observed side effects.